- Home
- INBK vs PBYI Comparison
INBK vs PBYI Comparison
Compare INBK & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBK
- PBYI
- Stock Information
- Founded
- INBK 1999
- PBYI 2010
- Country
- INBK United States
- PBYI United States
- Employees
- INBK N/A
- PBYI N/A
- Industry
- INBK Major Banks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- INBK Finance
- PBYI Health Care
- Exchange
- INBK Nasdaq
- PBYI Nasdaq
- Market Cap
- INBK 196.2M
- PBYI 175.7M
- IPO Year
- INBK N/A
- PBYI N/A
- Fundamental
- Price
- INBK $27.50
- PBYI $3.40
- Analyst Decision
- INBK Buy
- PBYI Strong Buy
- Analyst Count
- INBK 4
- PBYI 1
- Target Price
- INBK $34.50
- PBYI $7.00
- AVG Volume (30 Days)
- INBK 61.2K
- PBYI 331.8K
- Earning Date
- INBK 07-23-2025
- PBYI 07-31-2025
- Dividend Yield
- INBK 0.87%
- PBYI N/A
- EPS Growth
- INBK 27.37
- PBYI 143.51
- EPS
- INBK 2.40
- PBYI 0.77
- Revenue
- INBK $114,609,000.00
- PBYI $232,709,000.00
- Revenue This Year
- INBK $6.41
- PBYI N/A
- Revenue Next Year
- INBK $17.52
- PBYI N/A
- P/E Ratio
- INBK $11.55
- PBYI $4.35
- Revenue Growth
- INBK 20.13
- PBYI 2.68
- 52 Week Low
- INBK $19.54
- PBYI $2.23
- 52 Week High
- INBK $43.27
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- INBK 59.23
- PBYI 44.64
- Support Level
- INBK $26.82
- PBYI $3.36
- Resistance Level
- INBK $28.15
- PBYI $3.63
- Average True Range (ATR)
- INBK 0.76
- PBYI 0.12
- MACD
- INBK -0.08
- PBYI -0.02
- Stochastic Oscillator
- INBK 46.28
- PBYI 4.29
About INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.